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Abstract
Background: Traditional one-session exposure therapy (OST) in which a patient is gradually exposed to feared
stimuli for up to 3 h in a one-session format has been found effective for the treatment of specific phobias.
However, many individuals with specific phobia are reluctant to seek help, and access to care is lacking due to
logistic challenges of accessing, collecting, storing, and/or maintaining stimuli. Virtual reality (VR) exposure therapy
may improve upon existing techniques by facilitating access, decreasing cost, and increasing acceptability and
effectiveness. The aim of this study is to compare traditional OST with in vivo spiders and a human therapist with
a newly developed single-session gamified VR exposure therapy application with modern VR hardware, virtual
spiders, and a virtual therapist.
Methods/design: Participants with specific phobia to spiders (N = 100) will be recruited from the general public,
screened, and randomized to either VR exposure therapy (n = 50) or traditional OST (n = 50). A behavioral approach
test using in vivo spiders will serve as the primary outcome measure. Secondary outcome measures will include
spider phobia questionnaires and self-reported anxiety, depression, and quality of life. Outcomes will be assessed
using a non-inferiority design at baseline and at 1, 12, and 52 weeks after treatment.
Discussion: VR exposure therapy has previously been evaluated as a treatment for specific phobias, but there has
been a lack of high-quality randomized controlled trials. A new generation of modern, consumer-ready VR devices
is being released that are advancing existing technology and have the potential to improve clinical availability and
treatment effectiveness. The VR medium is also particularly suitable for taking advantage of recent phobia treatment
research emphasizing engagement and new learning, as opposed to physiological habituation. This study compares
a market-ready, gamified VR spider phobia exposure application, delivered using consumer VR hardware, with the
current gold standard treatment. Implications are discussed.
Trial registration: ClinicalTrials.gov identifier NCT02533310. Registered on 25 August 2015.
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Background
Specific phobias are second only to major depression for
lifetime prevalence of mental health disorders in the
United States (16.6 % vs 15.6 %) [1]. The prevalence is
somewhat reduced in older individuals (8.7 %) [2]. Esti-
mates suggest 60–80 % of those with specific phobia are
hesitant to seek help [3]. Some phobias are far more
common than others [4], with half of reported phobias
being fear of either heights or animals [5]. Spider phobia
is among the most prevalent of animal phobias and is
the most studied. The consequences of anxiety, worry,
and avoidance behavior can have a large impact on qual-
ity of life, work, and leisure activities [6].
Exposure-based therapies in which an individual is sys-
tematically and repeatedly presented with a feared or
avoided internal or external cue is highly effective in re-
ducing anxiety disorders [7, 8]. Compared with imaginal
exposure, evidence indicates that an in vivo (naturalistic
setting) stimulus is the preferable exposure treatment
method for specific phobia [6]. One-session therapy
(OST) is considered the intervention of choice for in
vivo specific phobia treatment in adults and children
[9, 10]. OST sessions typically last up to 3 h and consist
of graduated exposure to phobic stimuli, positive
reinforcement, therapist modeling of non-phobic behav-
ior, and cognitive restructuring of catastrophic beliefs
[11].
The benefits of exposure therapy are limited by issues
pertaining to both therapist and patient. Access to
evidence-based treatments has been lacking [12], likely
commensurate with the challenges of therapists locating
appropriate material and/or stimuli, difficulties with con-
ducting exposure work outside the clinic, and maintain-
ing stimuli such as animals and insects. Even when these
resources are available, participants may refuse to engage
in therapy. Once explained, exposure therapy is turned
down by 30 % of subjects [13], and this percentage is
estimated to be significantly higher for OST if the end-
point is discussed beforehand [12]. Return of fear of the
feared stimuli following treatment can also occur at a
later date [14].
Virtual reality (VR) technology involving head-mounted,
motion-tracked displays, accompanied by realistically ren-
dered 3D computer-animated environments [15], offers
researchers the opportunity to recreate phobic stimuli,
manipulate and tailor key variables associated with stimu-
lus presentation (color, size, and movement), context,
scheduling, and intensity of exposure according to the
patient’s needs, as well as to extract unprecedented
amounts of data, such as gaze focus [16]. Previous genera-
tions of VR have already been used successfully in mental
health treatments [17] for fear of flying, heights, public
speaking, and spider phobia, among others [18]. VR thus
has the potential to greatly increase accessibility and
effectiveness of exposure treatments. In a survey of 777
undergraduate students who scored high in fear of spiders,
more than 80 % expressed a preference for VR exposure
treatment over in vivo treatment [19]. In recent studies,
researchers have evaluated the unique opportunity of VR
to inexpensively and relatively easily alter the context of
exposure, an important moderator of treatment resur-
gence [20]. Participants treated using VR in multiple envi-
ronments [21], and participants treated by exposure to
spiders using video recordings of multiple areas of a house
rather than a single area [22], were less likely to have
return of fear following an aversive event.
Serious games designed for purposes other than enter-
tainment and allowing users to experience situations im-
possible or dangerous in real life [23], with gamified
elements such as points and goals to increase engage-
ment [24], may provide a particularly promising ad-
vancement in exposure therapy. As reviewed by Botella
et al. [25], game elements may reduce distress as com-
pared with traditional exposure therapy [26]. Recom-
mendations that patients continue to confront phobic
stimuli posttreatment [12] may be facilitated by gamified
VR content that can be played again and again [25].
The potential of VR notwithstanding, the quality of past
VR exposure therapy research has historically been poor
[27]. Well-designed randomized controlled trials are re-
quired before implementation in clinical practice can be
recommended. Further, recent advances in VR technology
have enabled unprecedented realistic stimuli to be ren-
dered with less intrusive equipment, minimizing the risk
of nausea and allowing longer sessions, though careful ap-
plication design is still required [28]. A new generation of
VR systems produced by some of the world’s largest tech-
nology companies, such as Sony (Project Morpheus),
Microsoft (Hololens), HTC (Vive), and Facebook (Oculus
Rift), promises to change VR from a professional niche
product costing as much as $35,000 to a consumer prod-
uct priced around $599 plus the cost of a competent com-
puter [29]. Other developments in VR include the use of
smartphone-based systems such as the Samsung Gear VR,
used in the present study, the cost of which is negligible
($99 USD) if paired with a user’s preexisting smartphone
[30]. From a research perspective, using VR can also re-
duce some of the complexity of carrying out exposure
treatments, improve standardization of protocols and
cost-effectiveness, and enable at-home self-care [31].
The parallel-group randomized controlled trial described
in this protocol is designed to investigate non-inferiority of
a novel, gamified VR OST program for spider phobia by
comparison with traditional OST.
Methods/design
This randomized controlled trial is registered in the
ClinicalTrials.gov database (NCT02533310) and has
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received ethical approval from the Stockholm Regional
Ethical Review Board (Dnr 472-31). Written informed
consent will be obtained from all participants at the pre-
measurement occasion.
Procedure
To recruit a diverse sample, multiple recruitment
methods will be used, primarily postings in online for-
ums and through coverage in national television, news-
papers, and magazines [32]. Potential participants will be
directed to the study website (www.vimse.se), where they
will find more information about the study and can
complete the online screening battery. Participants
meeting inclusion criteria will travel to Stockholm Uni-
versity to complete the premeasurement, including self-
rating scales, a diagnostic interview, and a Behavioral
Approach Test (BAT). If suitable for inclusion, partici-
pants will be randomized and, approximately 1 week
after the premeasurement occasion, will complete the
allocated treatment session. Posttreatment measure-
ments will take place approximately 1 week after the
treatment session. Additional follow-up measurements
are planned after 12 and 52 weeks. See Fig. 1 for the
study flowchart.
Subjects will be randomized to treatment arms (using
a true random number generator: www.random.org)
after completing the premeasurement in preset blocks of
4, 6, 8, or 10 (randomly sized) with even group alloca-
tion in each block. Randomization will be performed by
a research assistant not otherwise involved in the study,
and allocation will be blinded to all but the treatment
coordinator and the assigned therapist. As in most psy-
chological research, blinding participants to treatment
allocation is not feasible. For ethical reasons, subjects
are informed at premeasurement of the two possible
treatment allocations, and their preference (and strength
thereof ) is noted to enable investigation of mediating
effects of treatment preference. The therapist adminis-
tering the posttreatment assessment will be blinded to
treatment allocation until all outcome measures have
been completed.
All data gathered during the study will be stored an-
onymously. No contractual agreements limit access by
other investigators to this data or to final datasets, and
upon completion the dataset generated in this trial will
be published in a data repository (e.g., Dryad or fig-
share), accompanied by the script files to reproduce the
statistical analyses.
Sample
The sample will consist of 100 adults (age ≥18 years). To
be included, participants need to reside in Sweden, be
fluent in Swedish, and have the ability to travel to the
study location on five separate occasions (pretest, treat-
ment, posttest, and two follow-up occasions). Exclusion
criteria include ongoing psychotherapy or psychotropic
medication (unless on stable dosage for the previous
3 months and no changes planned during the study
period), indications of suicidal ideation or other serious
mental disorder (e.g., substance misuse, bipolar disorder,
psychosis), and lack of stereoscopic vision or balance
problems that would hinder experiencing the VR envir-
onment. To meet inclusion criteria, participants must
score 9 or less on the BAT (see below) and meet the cri-
teria set forth in the Diagnostic and Statistical Manual
of Mental Disorders, Fifth Edition (DSM-5), for specific
phobia, assessed using the Structured Clinical Interview
for DSM Disorders [33] adapted for DSM-5 criteria [34].
Measures
Primary outcome measure
Change from baseline on the BAT will serve as the pri-
mary outcome measure. To study the real-world effects
of VR therapy, all participants will complete the same
BAT featuring a real spider. The BAT [35] will feature
13 steps (scored 0–12) corresponding to sequentially
closer contact with the spider. See Table 1 for sequence
details. The BAT will begin with participants standing
outside a room (approximately 3 × 5 m large) where
there will be a table placed farthest away from the door,
on which a transparent container (about 40 × 30 × 19 cm
large) will house the spider (medium-sized; see below).





















52 week follow-up 
Fig. 1 Study flowchart. BAT Behavioral Approach Test
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the exercise is to pick up and hold the spider in their
hands for 20 seconds. They will be encouraged to do
their best but will be told that they can abort the exer-
cise at any time. A pretreatment score of 9 or less [36]
will be required for study inclusion.
Secondary outcome measures
In addition to the BAT, subjects will complete two self-
report measures of fear toward spiders: the Spider
Phobia Questionnaire (SPQ) [37] and the Fear of Spiders
Questionnaire (FSQ) [38]. The Generalized Anxiety Dis-
order 7-item scale (GAD-7) [39] will be used to measure
generic anxiety symptoms, and the Patient Health
Questionnaire-9 (PHQ-9) [40] will be used to evaluate
depression symptoms. Subjective quality of life will be
measured with the Brunnsviken Brief Quality of life scale
(BBQ) [41]. Meeting diagnostic criteria for specific pho-
bia in the 12- and 52-week follow-up measurements will
also serve as a secondary outcome measure. Swedish
translations of all the self-rating scales will be used.
Other measures
At premeasurement, all participants complete the treat-
ment Credibility/Expectancy Questionnaire (CEQ) [42]
for both the traditional OST and VR treatments (in quasi-
randomized order). Participants also complete the CEQ at
postmeasurement with re-phrased items that ask respon-
dents to evaluate their completed treatment. A number of
additional surveys will be used to determine the influence
of moderating factors on VR treatment outcome. Immedi-
ately following treatment, VR-treated participants will an-
swer the Simulator Sickness Questionnaire (SSQ) [43], a
measure of participant discomfort during treatment. At
postmeasurement, VR-treated participants will further
complete the iGroup Presence Questionnaire (IPQ) [44], a
measure of the sense of actually being in the virtual envir-
onment, and the System Usability Scale (SUS) [45], which
assesses product complexity and ease of use. At postmea-
surement, all participants will complete the Adverse Ef-
fects Questionnaire, a novel measurement tool used to
assess side effects of psychological treatments, as proposed
by Rozenthal et al. [46]. Finally, at 12-week and 52-week
follow-up, patients will answer questions regarding fre-
quency and type of interactions with spiders since their
last visit, as well as other forms of treatment received.
Interventions
Traditional OST
Traditional OST treatment sessions will be held with
participants on a one-to-one basis with clinical psychol-
ogists or clinical psychologists in their final year of train-
ing, all with past clinical cognitive behavioral therapy
experience. All OST therapists will receive regular
supervision from an experienced clinical psychologist
and psychotherapist.
Traditional OST for spider phobia consists of a com-
bination of gradated exposures to increasingly large, nat-
urally occurring in vivo spiders and model learning of
healthy, non-phobic behavior as demonstrated by the
therapist [12]. Spiders used in traditional OST (and the
BAT) will be harmless common varieties indigenous to
the region, primarily of the genus Tegenaria (T. domes-
tica and T. atrica). Spiders will be classified according to
size: small (5–15 mm), medium (15–25 mm), or large
(>25 mm).
The goal of OST is to bring patients a greater sense of
control and a recognition that their feared catastrophic
outcome will not occur (e.g., they will not have a heart
attack). OST is performed for a maximum 3-h duration
during a morning or afternoon. The patient is first ex-
plained the rationale and content of the treatment, then
their catastrophic beliefs and safety behaviors are ex-
plored and avoidance activities are normalized. Partici-
pant modeling encourages careful observation by
patients and that they not close their eyes or look away.
Subjective units of distress (SUD) ratings are used to de-
termine when to move on to a more challenging stage of
treatment (100 % denotes the most anxiety-provoking
situation experienced in relation to the phobia). Humor
can be used to put the patient’s reactions into perspec-
tive and reduce the patient’s anxiety [47].
The initial graduated exposure step (featuring a small
spider) teaches the patient to capture a spider with a
glass with the intention of removing it from the building.
The next exposure step has the patient touch various
parts of the spider. Interactions with the spider are best
Table 1 Behavioral Approach Test step specifications
Score Details
0 Refusal to enter room
1 Enters room but stops before covering one-fifth of the
distance to the container
2 Stops before covering two-fifths of the distance to the
container
3 Stops before covering three-fifths of the distance to the
container
4 Stops before covering four-fifths of the distance to the
container
5 Stops before covering all of the distance to the container
6 Reaches the table with the container
7 Touches the container
8 Removes the lid of the container
9 Puts a hand inside the container
10 Touches the spider with at least one finger
11 Holds spider in hands for less than 20 seconds
12 Holds spider in hands for 20 seconds or more
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organized as behavioral experiments in which the
patient’s beliefs about what may occur are tested against
reality. The exposure steps that follow have the spider
crawl first on the patient’s hand then up to the elbow,
and finally the spider is allowed to crawl on the patient’s
body, from the knee to the waist and from the shirt up
to the neck. These steps are then repeated using first a
medium spider and then a large spider. The final stage
has the patient handle two spiders, one in each hand,
and an overlearning step can be added in which the
spider crawls on the patient’s hair and cheek. The pa-
tient should have no or low anxiety in the last exposure
stages and should no longer believe their catastrophic
cognitions.
Virtual reality one-session therapy
VR OST was designed as a serious game [23] with
game progression entailing gradually increased stimuli
intensity. The application consists of a number of
zones, each containing three types of gamified tasks
for the user to complete: (1) looking at spiders, (2)
interacting with spiders to complete rudimentary
game mechanics, and (3) a task where the user is
approached by a spider. With completion of tasks
and progression through the zones, spider stimuli be-
come increasingly more intense, from a cute, cartoon-
ish spider through realistically depicted tarantulas. See
Fig. 2 for a screenshot from the application. Two
virtual environments will be used: a living room en-
vironment and an outdoor suburban backyard envir-
onment. User input is strictly gaze-derived and is
used for the interactive game mechanics, reporting
SUD and more. Once initiated, the application is fully
automated (i.e., no therapist action required) and in-
cludes a system for saving and compiling SUD and
other input, a virtual therapist providing instructions
through voiceover, support and summaries of pro-
gress, and information about spiders. Unlike the OST
treatment, participants in the VR condition will be seated
throughout the duration of therapy, but both groups will
be time-limited to 3-h duration. Although the VR treat-
ment is automated, a clinical psychologist will be in
attendance (one-to-one) with the participant in case of
technical or other difficulties.
In this study, the Samsung Gear VR platform (powered
by a Samsung Galaxy Note 4 or Galaxy S6, both running
Android 5.0) will be used to create the VR environment.
Availability of the VR application on other VR platforms
(e.g., Oculus and Vive) is planned.
Analyses
Data will be analyzed on an intention-to-treat basis,
using mixed effects models [48]. This trial was powered
to detect a non-inferiority margin of a 2-point between-
group difference, with a standard deviation of 4. The
margin and standard deviation were based on previous
research on traditional OST [36]. In accordance with the
non-inferiority design, we hypothesize that the lower
bound of the 95 % confidence interval of the between-
group difference will not be larger than 2. On the basis
of these parameters (and 80 % power), the study will re-
quire 50 participants assigned to each group (N = 100
total). In addition to the non-inferiority analyses, stand-
ard mixed models will be used to investigate effects of
time and group on primary and secondary outcome
measures. Within- and between-group effect sizes will
be calculated using Cohen’s d. The influence on out-
comes of demographic and other non-clinical vari-
ables (e.g., experience with gaming) will also be
examined. All design, implementation, and reporting
will be carried out in accordance with CONSORT and
SPIRIT guidelines [49–51].
Discussion
The aim of this study is to evaluate the effectiveness of
VR exposure therapy compared with traditional one-
session exposure therapy using a randomized controlled
design and subjects diagnosed with spider phobia. The
Fig. 2 Screenshot from the virtual reality application
Miloff et al. Trials  (2016) 17:60 Page 5 of 8
introduction of modern VR headsets combined with
powerful but relatively inexpensive computers capable of
displaying realistic stimuli, in addition to the historical
lack of high-quality randomized controlled trials [52],
suggest that this is an opportune time to make use of
this rapidly advancing technology and translate it into
clinically validated mental health treatments. VR expos-
ure therapy has already been theoretically and empiric-
ally evaluated to be well-suited for the treatment of
specific phobias [53]. The authors of a recent meta-
analysis [54] provided additional evidence based on
behavioral assessment rather than self-report of in-
ternal states. VR exposure-treated subjects, in their
review of 14 studies, improved significantly after
treatment (g = 1.23) and compared with control sub-
jects (g = 1.41). No significant differences were identi-
fied after treatment and in follow-up between in vivo
and VR exposures.
Conducting VR exposure therapy using modern, com-
mercially available VR equipment may prove even more
powerful. In addition to the evaluation of modern VR
hardware, our intent in this study is also to evaluate a
newly developed, gamified exposure application for the
treatment of specific phobias. The software includes ad-
vancements such as multiple open-ended exposure sce-
narios relying on gamification to improve engagement
and interest; multiple stimulus intensity variables such
as appearance (small to large spiders, cartoon-like to
hairy), behavior (more or less predictable, static, and ag-
gressive), a variable number of spiders, and changes in
lighting and protective barriers (such as caged or not); a
virtual therapist that guides the participant in the use of
the application and provides psychoeducation and expert
advice about spiders; and inclusion of a gaze direction
trackpad to allow participants to interact with the stimuli.
Recent evidence indicates that treatment benefits of
exposure therapy accrue as a result of new inhibitory
learning and not habituation of the conditioned response
to phobic stimuli [55]. Physiological habituation (viz.,
reduced heart rate and galvanic skin response) may serve
as a safety signal alleviating fear in the short term but
inhibiting long-term learning and extinction [56]. Ser-
ious game treatments in which there is a sense of play,
interactivity, flow, and creative solutions have the poten-
tial to promote new learning [57]. In an exposure ther-
apy context, these should create engagement (rather
than avoidance) by producing a mismatch between ex-
pectancy and outcome and require flexible responding
[55]. In a study in which a fear of heights group received
random levels of exposure intensity and approached
stimuli in multiple ways versus a steady intensity in-
crease group, researchers found improved fear reduc-
tion in the former, without a need for physiological
habituation [58].
Limitations of the present study include an exposure
application that involves multiple unique design specifi-
cations, making disentangling of specific therapeutic fac-
tors difficult. Despite the complete automation of the
VR application, psychologists will be in attendance to
resolve technical difficulties and ensure treatment com-
pliance and will be present to assist patients if needed.
Future studies will benefit from having the patient
administer VR treatment independently to ensure true
isolation of treatment effects. In addition, physiological
monitoring of subjects will not be possible during this
study but may prove helpful in interpreting the results
of future studies.
In sum, spider phobia is a common disorder [1] that
has a negative impact on life, work, and leisure activities
[6] but goes largely untreated [3]. VR exposure therapy
may provide improvements in efficacy [15], access,
standardization of protocols, and cost-effectiveness [31].
Although not evaluated in this study, virtual OST also
has the potential to conveniently continue maintenance
therapy once regular treatment has been completed.
This study is, to our knowledge, the first to test the effi-
cacy of a modern, market-ready VR application for the
treatment of spider phobia, and it will assist in the devel-
opment of a new method for the delivery of evidence-
based treatments.
Trial status
At time of initial manuscript submission (August
2015), recruitment was ongoing. Enrolment and the
active treatment period are expected to be completed
in January 2016.
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